Last reviewed · How we verify
Eflornithine Topical
Eflornithine Topical is a Ornithine decarboxylase inhibitor Small molecule drug developed by Khyber Teaching Hospital. It is currently FDA-approved for Reduction of unwanted facial hair in women. Also known as: Eflornithine cream.
Eflornithine inhibits ornithine decarboxylase, reducing polyamine synthesis and slowing hair growth.
Eflornithine inhibits ornithine decarboxylase, reducing polyamine synthesis and slowing hair growth. Used for Reduction of unwanted facial hair in women.
At a glance
| Generic name | Eflornithine Topical |
|---|---|
| Also known as | Eflornithine cream |
| Sponsor | Khyber Teaching Hospital |
| Drug class | Ornithine decarboxylase inhibitor |
| Target | Ornithine decarboxylase (ODC) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Eflornithine is an irreversible inhibitor of ornithine decarboxylase (ODC), an enzyme essential for polyamine biosynthesis. Polyamines are required for cell proliferation and hair follicle growth. By depleting polyamines in hair follicles, eflornithine slows the growth rate of hair, making it finer and lighter over time.
Approved indications
- Reduction of unwanted facial hair in women
Common side effects
- Skin irritation
- Acne
- Rash
- Folliculitis
Key clinical trials
- Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer (PHASE2)
- Comparison of a Face Cream Plus a Laser Procedure and Face Cream Alone in Treatment of Excessive Face Hairs in Female (PHASE4)
- Efficacy of Eflornithine Hydrochloride Cream in the Treatment of Melasma: A Randomized, Double-blinded, Split-face Controlled Study (PHASE2)
- Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial (PHASE4)
- Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis (PHASE2)
- Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin (PHASE2)
- Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eflornithine Topical CI brief — competitive landscape report
- Eflornithine Topical updates RSS · CI watch RSS
- Khyber Teaching Hospital portfolio CI
Frequently asked questions about Eflornithine Topical
What is Eflornithine Topical?
How does Eflornithine Topical work?
What is Eflornithine Topical used for?
Who makes Eflornithine Topical?
Is Eflornithine Topical also known as anything else?
What drug class is Eflornithine Topical in?
What development phase is Eflornithine Topical in?
What are the side effects of Eflornithine Topical?
What does Eflornithine Topical target?
Related
- Drug class: All Ornithine decarboxylase inhibitor drugs
- Target: All drugs targeting Ornithine decarboxylase (ODC)
- Manufacturer: Khyber Teaching Hospital — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Reduction of unwanted facial hair in women
- Also known as: Eflornithine cream
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing